Thursday, July 17, 2025 7/17/2025

Novel TLR-4 Agonists as Vaccine Adjuvants

Award Number: R43AI174478
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/02/2023
PERIOD OF PERFORMANCE END DATE: 04/30/2025

Group Awards By:

View Award Description

Novel TLR-4 Agonists as Vaccine Adjuvants - Abstract/Project Summary Along with the many benefits of a global economy hides the ever-present risk for the world wide spread of infectious disease. While significant outbreaks of the flu in the recent past involving millions of individuals could be contained, the emergence and rapid spread of the SARS-CoV-2 virus revealed how vulnerable and unprepared the world population was to combat a previously unknown human pathogen. To limit the loss of life and economic disruption resulting from a future global event, steps toward pandemic preparedness are needed. A major component of being prepared is having the necessary tools available to act quickly to protect human health. In the ongoing pandemic, vaccines emerged as the best way to protect healthy populations and prevent hospitalization or death among those individuals who become infected. However, vaccine availability and logistical constraints regarding their distribution has left a significant proportion of the world’s population still waiting for their first dose. The ability to quickly discover and develop vaccines which can be administered on a large scale is one solution towards solving this current problem. In support of this effort, it is the goal of this Phase I project to identify TLR4 agonists with immunostimulatory activity suitable for the development of safe and effective vaccine adjuvants. To achieve this goal, we will combine our years of expertise in medicinal chemistry and vaccine research and development toward completing the following specific aims: 1) Establish efficient synthesis routes for pure tri-acylated monophosphate derivatives of sucrose; 2) Identify TLR4 agonists using cell-based assays, determine their cytokine production profiles, and compare them to the full TLR4 agonist mono-phospholipid A (MPLA); and 3) Determine the immunogenic potency and safety profiles of selected sucrose based TLR4 agonists in mice and compare them against an existing subunit protein vaccines targeting West Nile Virus. We expect the product from this research to enable the development of novel adjuvants to support the preparation of new vaccines to combat current and future disease threats.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $204,860 )
2024	2024	HAWAII BIOTECH, INC.	650 IWILEI RD	HONOLULU	HI	96817	HONOLULU	USA	Allergy and Infectious Diseases Research	000	2	4/4/2024	NON-COMPETING CONTINUATION	$204,860
														Subtotal = $204,860

Issue Date FY: 2023 ( Subtotal = $203,485 )
2023	2023	HAWAII BIOTECH, INC.	650 IWILEI RD STE 204	HONOLULU	HI	96817	HONOLULU	USA	Allergy and Infectious Diseases Research	000	1	5/2/2023	NEW	$203,485
														Subtotal = $203,485

Grand Total All Awards = $408,345

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel TLR-4 Agonists as Vaccine Adjuvants

Award Number: R43AI174478

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/02/2023

PERIOD OF PERFORMANCE END DATE: 04/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer